journal
MENU ▼
Read by QxMD icon Read
search

Advances in Therapy

journal
https://www.readbyqxmd.com/read/28526997/nafld-as-a-sexual-dimorphic-disease-role-of-gender-and-reproductive-status-in-the-development-and-progression-of-nonalcoholic-fatty-liver-disease-and-inherent-cardiovascular-risk
#1
REVIEW
Stefano Ballestri, Fabio Nascimbeni, Enrica Baldelli, Alessandra Marrazzo, Dante Romagnoli, Amedeo Lonardo
Nonalcoholic fatty liver disease (NAFLD) spans steatosis through nonalcoholic steatohepatis, cirrhosis, and hepatocellular carcinoma (HCC) associated with striking systemic features and excess cardiovascular and liver-related mortality. The pathogenesis of NAFLD is complex and multifactorial. Endocrine derangements are closely linked with dysmetabolic traits. For example, in animal and human studies, female sex is protected from dysmetabolism thanks to young individuals' ability to partition fatty acids towards ketone body production rather than very low density lipoprotein (VLDL)-triacylglycerol, and to sex-specific browning of white adipose tissue...
May 19, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28523624/erratum-to-evaluation-of-the-short-term-cost-effectiveness-of-ideglira-versus-continued-up-titration-of-insulin-glargine-u100-in-patients-with-type-2-diabetes-in-the-usa
#2
Barnaby Hunt, Michelle Mocarski, William J Valentine, Jakob Langer
No abstract text is available yet for this article.
May 18, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28508933/genetic-variants-within-key-nodes-of-the-cascade-of-antipsychotic-mechanisms-effects-on-antipsychotic-response-and-schizophrenia-psychopathology-in-a-naturalistic-treatment-setting-in-two-independent-korean-and-italian-samples
#3
Marco Calabrò, Stefano Porcelli, Concetta Crisafulli, Sheng-Min Wang, Soo-Jung Lee, Changsu Han, Ashwin A Patkar, Prakash S Masand, Diego Albani, Ilaria Raimondi, Gianluigi Forloni, Sofia Bin, Alessandro Mattiaccio, Vilma Mantovani, Tae-Youn Jun, Chi-Un Pae, Alessandro Serretti
INTRODUCTION: Schizophrenia (SCZ) is one of the most disabling psychiatric disorders. Genetic factors play an important role in both SCZ liability and its treatment outcome. In the present paper, we investigated the effects of several single nucleotide polymorphisms (SNPs) within ten strong candidate genes involved with antipsychotics (APs) mechanisms of action. METHODS: Two independent samples were investigated in the present study. Totals of 176 SCZ subjects and 326 controls of Korean ancestry, and 83 SCZ subjects and 194 controls of Italian ancestry were recruited and genotyped...
May 16, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28508307/duration-of-antiviral-prophylaxis-and-risk-of-herpes-zoster-among-patients-receiving-autologous-hematopoietic-stem-cell-transplants-a-retrospective-observational-study
#4
Dongmu Zhang, Thomas Weiss, Yu Feng, Lynn Finelli
INTRODUCTION: There are no real-world data on antiviral prophylaxis (AP) duration and risk of herpes zoster (HZ) given AP duration in patients receiving autologous hematopoietic stem cell transplants (auto-HSCT). The objectives of this study are to describe the duration of AP and to compare incidence of HZ by AP duration in auto-HSCT patients. METHODS: This is a retrospective, observational database (Marketscan(®)) study. This study included patients ≥18 years old who had auto-HSCT during 2009-2013, had chemotherapy within 60 days prior to auto-HSCT (latest chemotherapy date within the 60 days was the study enrollment date), and had continuous health plan enrollment for at least 365 days before and after the study enrollment date...
May 15, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28508306/multicenter-randomized-investigator-masked-study-comparing-brimonidine-tartrate-0-1-and-timolol-maleate-0-5-as-adjunctive-therapies-to-prostaglandin-analogues-in-normal-tension-glaucoma
#5
Shiro Mizoue, Koji Nitta, Motohiro Shirakashi, Akiyoshi Nitta, Shigeki Yamabayashi, Tairo Kimura, Toshihiko Ueda, Ryuji Takeda, Shun Matsumoto, Keiji Yoshikawa
INTRODUCTION: This study compared the efficacy and safety of adjunctive brimonidine tartrate 0.1% ophthalmic solution (brimonidine) and timolol maleate 0.5% ophthalmic solution (timolol) in prostaglandin analogue (PGA)-treated normal-tension glaucoma (NTG), assessing the non-inferiority of brimonidine in terms of intraocular pressure (IOP) reduction. METHODS: In this multicenter, randomized, investigator-masked, parallel-group, clinical study, adjunctive brimonidine or timolol was administered twice daily for 12 weeks in eyes with NTG that had been treated with PGA for at least 90 days and required additional treatment despite an IOP of 16 mmHg or less...
May 15, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28502036/perceptions-of-painful-diabetic-peripheral-neuropathy-in-south-east-asia-results-from-patient-and-physician-surveys
#6
Rayaz A Malik, Emre Aldinc, Siew-Pheng Chan, Chaicharn Deerochanawong, Chii-Min Hwu, Raymond L Rosales, Chun-Yip Yeung, Koichi Fujii, Bruce Parsons
There are no data on physician-patient communication in painful diabetic peripheral neuropathy (pDPN) in the Asia-Pacific region. The objective of this study was to examine patient and physician perceptions of pDPN and clinical practice behaviors in five countries in South-East Asia. Primary care physicians and practitioners, endocrinologists, diabetologists, and patients with pDPN completed separate surveys on pDPN diagnosis, impact, management, and physician-patient interactions in Hong Kong, Malaysia, the Philippines, Taiwan, and Thailand...
May 13, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28502035/prospective-observational-post-marketing-study-of-tafluprost-for-glaucoma-and-ocular-hypertension-effectiveness-and-treatment-persistence
#7
Yasuaki Kuwayama, Masako Hashimoto, Reiko Kakegawa, Akio Nomura, Fumiki Shimada
INTRODUCTION: The aim of this study was to investigate the long-term intraocular pressure (IOP)-lowering effect and safety of tafluprost, a prostaglandin analogue, in actual clinical practice and to determine persistency of tafluprost as an indicator of its benefit-risk balance. METHODS: This was a large-scale, post-marketing, multicenter, non-interventional, open-label, long-term study. Patients with glaucoma or ocular hypertension who initiated tafluprost treatment were registered and prospectively observed over a 2-year period in the real-world setting in Japan...
May 13, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28493056/non-vitamin-k-oral-anticoagulants-for-stroke-prevention-in-special-populations-with-atrial-fibrillation
#8
REVIEW
Arnaud Bisson, Denis Angoulvant, Raphael Philippart, Nicolas Clementy, Dominique Babuty, Laurent Fauchier
Atrial fibrillation (AF) is associated with an increased risk of ischemic stroke or systemic embolism compared with normal sinus rhythm. These strokes may efficiently be prevented in patients with risk factors using oral anticoagulant therapy, with either vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) (i.e., direct thrombin inhibitors or direct factor Xa inhibitors). Owing to their specific risk profiles, some AF populations may have increased risks of both thromboembolic and bleeding events...
May 10, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28484955/ranibizumab-in-the-treatment-of-diabetic-macular-edema-a-review-of-the-current-status-unmet-needs-and-emerging-challenges
#9
REVIEW
Nikolaos Dervenis, Athanasia Maria Mikropoulou, Paris Tranos, Panagiotis Dervenis
Diabetic retinopathy (more specifically diabetic macular edema, DME) is the most common cause of loss of vision in the working population in developed countries. Anti-vascular endothelial growth factor (anti-VEGF) agents considerably changed the treatment algorithms and improved prognosis of center-involving DME. Ranibizumab was the first approved anti-VEGF agent that revolutionized DME treatment. The vast increase in the number of patients undergoing intravitreal treatment and the role of anti-VEGF pharmacotherapy as the mainstay of DME treatment have triggered several challenges...
May 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28484954/repurposing-pentoxifylline-for-the-treatment-of-fibrosis-an-overview
#10
REVIEW
Wei Xiong Wen, Siang Yin Lee, Rafaella Siang, Rhun Yian Koh
Fibrosis is a potentially debilitating disease with high morbidity rates. It is estimated that half of all deaths that occur in the USA are attributed to fibrotic disorders. Fibrotic disorders are characterized primarily by disruption in the extracellular matrix deposition and breakdown equilibrium, leading to the accumulation of excessive amounts of extracellular matrix. Given the potentially high prevalence of fibrosis and the paucity of agents currently available for the treatment of this disease, there is an urgent need for the identification of drugs that can be utilized to treat the disease...
May 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28484953/predicting-pre-emptive-discussions-of-biologic-treatment-results-from-an-openness-and-preference-survey-of-inflammatory-bowel-disease-patients-and-their-prescribers
#11
M Furaha Kariburyo, Lin Xie, Amanda Teeple, Haoran Tan, Michael Ingham
INTRODUCTION: It is important to compare patient and provider discrepancies on stated openness to and preference for biologics as well as predictors associated with initial discussions on biologic use. METHODS: Patients (N = 263) and physicians (N = 100) completed a self-administered Web-based survey assessing demographics, health characteristics, and behaviors related to inflammatory bowel disease (IBD) treatment. Bootstrap methods were used to check discrepancies between providers' and patients' stated openness to and preference for biologics...
May 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28455783/management-of-grass-pollen-allergy-with-5-grass-pollen-tablet-results-of-a-2-year-real-life-study
#12
Kija Shah-Hosseini, Eva-Maria Krudewig, Meike Hadler, Efstrathios Karagiannis, Ralph Mösges
INTRODUCTION: Allergen immunotherapy is the only treatment option for allergic rhinitis with disease-altering potential. It was the objective of this study to assess the effectiveness and tolerability of a 5-grass pollen tablet in a large population of non-selected grass pollen allergic patients, i.e. patients with different clinical profiles in daily clinical practice. METHODS: In a 2-year, prospective, open-label, multicenter, non-controlled, observational study patients were included from 327 centers across Germany...
April 28, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28455782/rpc4046-a-novel-anti-interleukin-13-antibody-blocks-il-13-binding-to-il-13-%C3%AE-1-and-%C3%AE-2-receptors-a-randomized-double-blind-placebo-controlled-dose-escalation-first-in-human-study
#13
Catherine S Tripp, Carolyn Cuff, Andrew L Campbell, Barbara A Hendrickson, Jeff Voss, Terry Melim, Chengbin Wu, Andrew D Cherniack, Kenneth Kim
INTRODUCTION: A unique anti-interleukin (IL)-13 monoclonal antibody, RPC4046, was generated on the basis of differential IL-13 receptor (R) blockade as assessed in a murine asthma model; the safety, tolerability, pharmacokinetics, and pharmacodynamics of RPC4046 were evaluated in a first-in-human study. METHODS: Anti-IL-13 antibodies with varying receptor blocking specificity were evaluated in the ovalbumin-induced murine asthma model. A randomized, double-blind, placebo-controlled, dose-escalation first-in-human study (NCT00986037) was conducted with RPC4046 in healthy adults and patients with mild to moderate controlled asthma...
April 28, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28452039/erratum-to-efficacy-of-zofenopril-vs-irbesartan-in-combination-with-a-thiazide-diuretic-in-hypertensive-patients-with-multiple-risk-factors-not-controlled-by-a-previous-monotherapy-a-review-of-the-double-blind-randomized-z-studies
#14
Stefano Omboni, Ettore Malacco, Claudio Napoli, Pietro Amedeo Modesti, Athanasios Manolis, Gianfranco Parati, Enrico Agabiti-Rosei, Claudio Borghi
No abstract text is available yet for this article.
April 27, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28447267/erratum-to-the-rituximab-biosimilar-ct-p10-in-rheumatology-and-cancer-a-budget-impact-analysis-in-28-european-countries
#15
László Gulácsi, Valentin Brodszky, Petra Baji, Fanni Rencz, Márta Péntek
No abstract text is available yet for this article.
April 26, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28439852/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-a-concise-review-with-a-comprehensive-summary-of-therapeutic-interventions-emphasizing-supportive-measures
#16
REVIEW
Jeremy A Schneider, Philip R Cohen
INTRODUCTION: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are two of the most severe dermatologic conditions occurring in the inpatient setting. There is a lack of consensus regarding appropriate management of SJS and TEN. PURPOSE: The scientific literature pertaining to SJS and TEN (subsequently referred to as SJS/TEN) is summarized and assessed. In addition, an interventional approach for the clinician is provided. METHODS: PubMed was searched with the key words: corticosteroids, cyclosporine, etanercept, intravenous immunoglobulin, Stevens-Johnson syndrome, and toxic epidermal necrolysis...
April 24, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28432647/the-gender-attention-observational-study-gender-and-hormonal-status-differences-in-the-incidence-of-adverse-events-during-cyclosporine-treatment-in-psoriatic-patients
#17
Delia Colombo, Giuseppe Banfi, Nicoletta Cassano, Alessandra Graziottin, Gino Antonio Vena, Giovanni Gualberto Fiori, Emanuela Zagni, Luca Stingeni, Sergio Chimenti, Enzo Berardesca, Giuseppe Micali, Giuseppe Albertini, Clara De Simone, Gilberto Bellia
INTRODUCTION: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients. METHODS: Multicenter, prospective, observational study conducted from May 2011 to June 2013...
April 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28432646/is-there-a-role-for-ivabradine-in-the-contemporary-management-of-patients-with-chronic-heart-failure-in-academic-and-community-heart-failure-clinics-in-canada
#18
Sherryn Roth, Carlos Fernando, Sadia Azeem, Gordon W Moe
INTRODUCTION: In patients with heart failure (HF) and reduced ejection fraction, increased heart rate (HR) is an independent risk factor for adverse outcomes. In systolic HF treatment with the If inhibitor ivabradine trial (SHIFT), Ivabradine improved survival when added to conventional treatment including β-blockers. However, the extent of benefit in the real world is unclear. We examined the characteristics of patients on guideline-directed therapy and determined who had SHIFT-like characteristics...
April 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28432645/efficacy-of-lomitapide-in-the-treatment-of-familial-homozygous-hypercholesterolemia-results-of-a-real-world-clinical-experience-in-italy
#19
Laura D'Erasmo, Angelo Baldassare Cefalù, Davide Noto, Antonina Giammanco, Maurizio Averna, Paolo Pintus, Paolo Medde, Giovanni Battista Vigna, Cesare Sirtori, Laura Calabresi, Chiara Pavanello, Marco Bucci, Carlo Sabbà, Patrizia Suppressa, Francesco Natale, Paolo Calabrò, Tiziana Sampietro, Federico Bigazzi, Francesco Sbrana, Katia Bonomo, Fulvio Sileo, Marcello Arca
INTRODUCTION: Homozygous familial hypercholesterolaemia (HoFH) is a rare form of inherited dyslipidemia resistant to conventional cholesterol-lowering medications so that lipoprotein apheresis (LA) is usually required. Lomitapide has been approved for the treatment of HoFH. The aim of this study was to evaluate the benefits of lomitapide in HoFH patients followed with the usual clinical care. METHODS: Clinical and biochemical data were retrospectively collected in 15 HoFH patients (10 with mutations in the LDLR gene and 5 in the LDLRAP1 gene) treated for at least 6 months with lomitapide in addition to lipid-lowering therapies (LLT) in different Lipid Clinics across Italy...
April 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28417318/patient-and-healthcare-professionals-preference-for-brenzys-vs-enbrel-autoinjector-for-rheumatoid-arthritis-a-randomized-crossover-simulated-use-study
#20
Marc Egeth, Jennifer Soosaar, Peter Nash, Denis Choquette, Ricardo Infante, Dena Rosen Ramey, Sevag Sahakian, Angela Lai, Jin Ju Kim, David Wu
INTRODUCTION: Brenzys was developed as an etanercept biosimilar of Enbrel. The aim of this study was to assess preference and perceived ease of use for the new Brenzys autoinjector compared to the currently available marketed Enbrel MYCLIC autoinjector (Australia) and Enbrel SureClick autoinjector (Canada) for the treatment of rheumatoid arthritis (RA). Because RA affects manual dexterity, ease of use of an autoinjector is a particularly important consideration in developing effective self-delivery of long-term courses of therapy...
April 17, 2017: Advances in Therapy
journal
journal
29381
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"